Fundamentos e objetivos: A interven&ccedil;&atilde;o coron&aacute;ria percut&acirc;nea (PCI) prim&aacute;ria da art&eacute;ria culpada pelo infarto agudo do mioc&aacute;rdio com supra de ST (STEMI) &eacute; o m&eacute;todo de escolha no tratamento deste quadro cl&iacute;nico. O objetivo do presente estudo foi encontrar a gest&atilde;o &oacute;tima dos doentes com STEMI que apresentavam pelo menos mais uma estenose de art&eacute;ria<a href="https://solaci.org/en/2015/06/24/prague-13-trial-2/" title="Read more" >...</a>

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients with multivessel. The primary endpoint of the study was mortality from any cause. Side end points were infarction, stroke, and revascularization. Propensity score was used to compare populations. Between 34819 patients were eligible 9223 patients in each group<a href="https://solaci.org/en/2015/06/24/best-similar-mortality-among-angioplasty-with-des-everolimus-and-surgery/" title="Read more" >...</a>

The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to<a href="https://solaci.org/en/2015/06/24/danami3-primary-angioplasty-to-culprit-vessel-versus-multivessel-guided-by-ffr/" title="Read more" >...</a>

This work included 18144 patients from 39 countries that were admitted pursuing an acute coronary syndrome (with or without ST segment elevation) randomized 1: 1 to receive the combination of simvastatin 40 mg / ezetimibe 10 mg (n = 9067) or simvastatin 40 mg alone (n = 9077). Of the total, 88% received a coronary<a href="https://solaci.org/en/2015/06/24/improve-it-the-combination-simvastatin-ezetimibe-reduces-post-sca-events/" title="Read more" >...</a>

The aim of this study was to assess treatment with the new anticoagulant Pegnivacogin and its specific antidote Anivamersen compared with bivalirudin in patients undergoing coronary angioplasty. The Pegnivacogin has an affinity for factor IXa with a longer shelf life to 24 hours and Anivamersen only has an affinity for Pegnivacogin. The combination of these<a href="https://solaci.org/en/2015/06/24/regulate-pci-reg1-with-an-unacceptable-rate-of-severe-allergic-reactions/" title="Read more" >...</a>

The aim of this study was to evaluate the safety and efficacy of long-term Evolocumab, an inhibitor of PCSK9 added to standard therapy versus standard therapy alone. Patients of five works in phase two and seven works in phase three were invited to participate in the extended program. These patients were randomized 2:1 to Evolocumab<a href="https://solaci.org/en/2015/06/24/osler-evolocumab-reduces-cardiovascular-events-compared-with-standard-statin-therapy/" title="Read more" >...</a>

The aim of this study was to evaluate Coronary angiography by multislice CT compared with standard therapy in patients at low or moderate risk with suggestive symptoms of coronary artery disease. 2073 patients were included in each branch with a mean follow up of 1.7 years. CT significantly increased the certainty of the diagnosis of<a href="https://solaci.org/en/2015/06/24/scot-heart-coronary-angiography-by-tomography-in-patients-with-suspected-coronary-artery-disease/" title="Read more" >...</a>

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy after confirming non-resistance to aspirin. &nbsp;Primary end point was a combination of death, infarction, emergency revascularization of target vessel, stroke and major bleeding. The study saw early termination due to<a href="https://solaci.org/en/2015/06/24/italic-plus-6-months-of-double-antiaggregation-for-no-less-than-24-months/" title="Read more" >...</a>

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET scan (positron emission tomography). The extension and severity of heart disease was assessed by angiography, and coronary flow reserve (CFR) was measured non-invasively by PET. After adjusting risk factors, ejection fraction, revascularization, etc, both the severity of angiographic<a href="https://solaci.org/en/2015/06/24/coronary-flow-reserve-is-associated-to-adverse-events-regardless-angiographic-severity/" title="Read more" >...</a>

Article 900 patients with asymptomatic diabetes mellitus were randomized to CT angiography vs. Standard management. Primary end point was a combination of death, infarction and unstable angina. 63% of patients randomized to CT angiography presented some degree of heart disease and 4.7% presented severe lesions. This resulted in more coronary interventions, more use of statins<a href="https://solaci.org/en/2015/06/24/factor-64-routine-coronary-ct-angiography-in-patients-at-high-risk-for-heart-disease/" title="Read more" >...</a>